Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
- GLP-3R is a casual nickname for retatrutide, an investigational triple agonist that targets GLP-1, GIP, and glucagon receptors.
- Phase 3 TRIUMPH trials show weight loss approaching bariatric surgery levels, with TRIUMPH-1 reporting 28.3% average loss at 80 weeks on 12 mg.1
- Common side effects include gastrointestinal issues during dose escalation and a unique dysesthesia (altered skin sensations) in about 12.5% of participants at the highest dose.
- Legitimate access currently comes through clinical trial enrollment on ClinicalTrials.gov or medically supervised peptide therapy with qualified healthcare providers.
- At Mirror Plastic Surgery, Dr. Akash Chandawarkar offers medically supervised peptide therapy with thorough screening, quality-tested products, and 24/7 physician access.
What GLP-3R Really Is: Retatrutide’s Name And Mechanism
“GLP-3R” is not an official drug name or a real receptor. It is a popular nickname for retatrutide, an investigational triple agonist from Eli Lilly that activates GLP-1, GIP, and glucagon receptors. Retatrutide is currently in Phase 3 clinical trials and is legally available only to clinical trial participants.
Retatrutide’s power comes from its triple mechanism, which builds on earlier incretin therapies. Each hormone plays a specific role:
- GLP-1 (Glucagon-like peptide-1): Slows gastric emptying, signals fullness to the brain, and stimulates glucose-dependent insulin release. This is the pathway behind Ozempic and Wegovy.
- GIP (Glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and influences fat metabolism. Tirzepatide (Mounjaro/Zepbound) already targets this pathway alongside GLP-1.
- Glucagon: Increases energy expenditure, helping the body burn more calories even at rest. This addition distinguishes retatrutide from existing therapies.
The informal “GLP-3” nickname highlights that retatrutide goes beyond the dual agonism of drugs like tirzepatide. It represents a “third generation” of incretin-based therapies. Scientifically, there is no “GLP-3 receptor.” The drug activates GIP, GLP-1, and glucagon receptors, which is why it is called a triple agonist. All data in this article comes from clinical trial results rather than approved product claims.
Phase 3 Clinical Trial Results: What The Data Shows
Eli Lilly’s TRIUMPH program is one of the largest Phase 3 clinical trial efforts for a weight-loss drug, with more than 5,800 participants across global registrational trials. As of mid-2026, five Phase 3 studies have reported positive results in general obesity, obesity with type 2 diabetes, obesity with cardiovascular disease, knee osteoarthritis, and obstructive sleep apnea. The table below summarizes key weight-loss outcomes from the three largest trials.
| Trial | Population | Key Weight-Loss Result (12 mg Dose) | Additional Findings |
|---|---|---|---|
| TRIUMPH-1 | Obesity/overweight without diabetes (n=2,339) | 28.3% average weight loss (70.3 lbs) at 80 weeks; 30.3% at 104 weeks1 | 45.3% achieved ≥30% weight loss; 65.3% reached BMI <301 |
| TRIUMPH-2 | Obesity with type 2 diabetes (n=1,152) | 20.8% average weight loss (49.6 lbs) at 80 weeks1 | A1C reduced by up to 1.6% from 7.7% baseline |
| TRIUMPH-3 | Severe obesity with cardiovascular disease (n=1,949) | 22.6% average weight loss (55.8 lbs) at 80 weeks1 | 37% reduction in triglycerides; 9.3 mmHg systolic BP reduction |
The 28.3% average weight loss in TRIUMPH-1 approaches outcomes typically seen with bariatric surgery. In the trial’s extension, participants with a baseline BMI of 35 or higher who stayed on 12 mg through 104 weeks lost an average of 30.3% of body weight, about 85 pounds1. Beyond weight loss, TRIUMPH-3 showed a 51.2% reduction in high-sensitivity C-reactive protein (hsCRP), along with meaningful drops in non-HDL cholesterol and systolic blood pressure. These results are unprecedented for a drug therapy, yet they still represent investigational data.
Safety And Side Effects To Discuss With Your Doctor
Retatrutide shares many side effects seen with other incretin-based therapies, especially in the digestive system. In TRIUMPH-1 at 12 mg, the most common adverse events were nausea (42.4% vs 14.8% placebo), diarrhea (32.0% vs 13.5%), constipation (26.1% vs 10.9%), and vomiting (25.3% vs 4.8%). These effects appeared mainly during dose escalation and usually eased with time.
Retatrutide also has a distinctive side effect not typical of GLP-1-only drugs: dysesthesia. This involves altered skin sensations such as tingling, burning, or hypersensitivity. In TRIUMPH-1, dysesthesia occurred in 12.5% of participants on 12 mg versus 0.9% on placebo, was usually mild to moderate, and most cases resolved during treatment.
Retatrutide trials exclude people with the following conditions:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
- History of pancreatitis
- Recent major cardiovascular events (within 90 days)
Every clinical trial participant receives close monitoring by medical professionals, and that oversight is essential. Because retatrutide affects multiple hormonal systems, safe dosing, titration, and monitoring require clinical expertise. For this reason, any use outside clinical trials should occur only under the supervision of a qualified healthcare provider who knows your full medical history.
How To Find And Enroll In A Legitimate Retatrutide Trial
Patients interested in authorized retatrutide studies can follow a clear process to explore eligibility and enrollment.
- Search ClinicalTrials.gov. ClinicalTrials.gov is the authoritative registry for clinical research. Search for “retatrutide” or “LY3437943” and filter by “Recruiting” to see active studies.
- Review Eligibility Criteria. Most obesity trials require a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related condition and a prior unsuccessful weight-loss attempt. Common exclusions include type 1 or type 2 diabetes in obesity-only trials, recent use of other weight-loss medications, pancreatitis history, MTC or MEN-2 history, and recent cardiovascular events.
- Contact The Study Site. Each listing includes a “Contacts and Locations” section. You can also call Eli Lilly’s Trial Information Center at 1-877-CTLILLY (1-877-285-4559) for help finding active sites.
- Understand The Commitment. Participation often lasts about 65 weeks and may involve around 18 visits, standardized lifestyle counseling, and weekly self-injections. Most trials are randomized and double-blind, so you may have only a 25–50% chance of receiving the active drug.
- Ask Key Questions. Before enrolling, ask about randomization ratio, total duration, visit schedule, follow-up after the trial, whether placebo participants later receive the active drug, and compensation for time and travel.
Legitimate clinical trials never charge participants. The study drug, visits, and lab work should be provided at no cost.
How Retatrutide Compares To Current Weight-Loss Medications
To see where retatrutide may fit among existing options, the table below compares its mechanism, FDA status, and expected weight loss with semaglutide and tirzepatide.
| Feature | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) | Retatrutide (Investigational) |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist | GLP-1 + GIP + glucagon triple agonist |
| FDA Status | Approved (2017/2021) | Approved (2022/2023) | Phase 3 trials ongoing |
| Average Weight Loss (Highest Dose) | ~15% (STEP-1, 68 weeks)1 | ~22.5% (SURMOUNT-1, 72 weeks)1 | 28.3% (TRIUMPH-1, 80 weeks)1 |
| Administration | Weekly injection | Weekly injection | Weekly injection |
Glucagon receptor agonism is the key distinction. By adding glucagon activation, retatrutide aims to increase energy expenditure on top of appetite suppression and blood sugar control from GLP-1 and GIP. This triple mechanism likely contributes to the stronger weight-loss results seen in trials. The numbers above come from separate studies with different designs, so they provide context rather than true head-to-head comparisons.
Retatrutide FDA Review Timeline
As of September 2026, retatrutide has not received FDA approval for any indication. Eli Lilly plans to submit a Biologics License Application (BLA) in Q1 2027 after positive results from five Phase 3 studies. The company has noted additional time is needed to finalize manufacturing and quality-control data. Based on this schedule and standard FDA review timelines, approval is expected sometime in 2027–2028.
Until then, patients can access retatrutide only through two legitimate paths:
- Clinical trial enrollment for eligible participants who accept the possibility of placebo.
- Medically supervised peptide therapy for those pursuing advanced peptide protocols under a qualified physician’s care.
The Dangers Of Buying “GLP-3R” Online
A June 2026 CBS News investigation found more than 120 websites selling or promoting retatrutide, including over 50 clinics staffed by licensed professionals. This pattern reflects a growing public health concern with real legal and medical consequences.
The unregulated market has produced several documented problems:
- The FDA has issued at least 14 warning letters to companies advertising retatrutide since 2024, and at least six continued offering it online.
- Exposures tracked by America’s Poison Centers rose to about 95 per month in early 2026, a 265% increase from late 2025.
- The U.S. Justice Department is prosecuting two cases involving retatrutide sales and prescriptions, and a Florida pharmacy was fined $250,000 for shipping 153 prescriptions into Ohio.
Products sold online as “retatrutide” or “GLP-3R” fall outside FDA oversight. These products lack verified purity, accurate dosing protocols, sterility guarantees, and medical monitoring for adverse events or drug interactions. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, stated there are no legal grounds to compound retatrutide: “Zero. None. None whatsoever.” The FDA has stated that retatrutide “has not been found safe or effective for any condition” and “cannot be manufactured or distributed except for investigational use.”
Patients interested in advanced peptide therapies protect themselves by working with qualified medical providers who use reputable suppliers with batch testing, clear dosing protocols, and ongoing supervision.
How Mirror Plastic Surgery Supports Safe Peptide Therapy
At Mirror Plastic Surgery in St. Petersburg, Florida, Dr. Akash Chandawarkar, a Harvard-educated, Johns Hopkins-trained, board-certified plastic surgeon, offers advanced peptide therapies within a concierge medical model focused on safety and long-term outcomes. He personally designs and supervises every peptide protocol. Before starting treatment, he reviews your full medical history and, when appropriate, orders comprehensive labs covering thyroid, liver, kidney, diabetes markers, and hormone levels. Peptides come only from reputable providers with rigorous batch testing, and patients receive direct 24/7 text access to Dr. Chandawarkar for questions, concerns, and refills.
Mirror Plastic Surgery offers GLP-3R compounding, a newer-generation peptide approach similar to GLP-1 therapies but reported to have fewer gastrointestinal side effects, a lower risk of muscle loss, and broader metabolic applications such as insulin resistance, weight management, and cardiovascular risk factors. Treatment occurs under medical supervision with appropriate screening and monitoring. Dr. Chandawarkar frequently advises patients to delay or avoid services that are not yet necessary, emphasizing durable results over short-term revenue.
Schedule A Consultation With Mirror Plastic Surgery to meet with Dr. Chandawarkar and see whether medically supervised peptide therapy fits your goals.
Key Takeaways: Your GLP-3R Action Plan
The points below summarize the most practical steps and facts to remember as you consider GLP-3R and related therapies.
- “GLP-3R” Is A Nickname. It refers to retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors.
- Phase 3 Results Are Strong But Still Investigational. The 28.3% average weight loss from TRIUMPH-1 approaches bariatric surgery outcomes, yet retatrutide remains under review.
- Side Effects Are Common And Need Monitoring. Gastrointestinal issues cluster during dose escalation, and dysesthesia is a unique effect to review with your provider.
- Clinical Trials Provide Legal Access. Search ClinicalTrials.gov for “retatrutide” or “LY3437943,” filter by “Recruiting,” and contact study sites directly. Do not pay to join a trial.
- FDA Review Will Take Time. Eli Lilly plans to file its BLA in Q1 2027, with likely approval in 2027–2028.
- Avoid Unregulated Online Peptides. Regulators are actively pursuing illegal sellers, and product quality is uncertain.
- Professional Oversight Is Essential. Whether through a clinical trial or a qualified provider such as Mirror Plastic Surgery, peptide therapy should always include medical supervision.
Talk With Dr. Chandawarkar About Your Options to get a personalized, evidence-based plan for your metabolic health.
Frequently Asked Questions
What Is The Difference Between GLP-1 And GLP-3R?
GLP-1 (glucagon-like peptide-1) is a natural hormone and the target of medications such as Ozempic and Wegovy. “GLP-3R” is a casual nickname for retatrutide, an investigational drug that targets three receptors: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. GLP-1 drugs act on a single pathway to reduce appetite and stimulate insulin release. Retatrutide adds GIP effects on fat metabolism and glucagon-driven increases in energy expenditure. There is no true “GLP-3 receptor”; the name reflects its role as a third-generation incretin therapy.
Are There Any Ongoing Retatrutide Trials I Can Join?
As of September 2026, several retatrutide trials are actively recruiting. The most reliable approach is to search ClinicalTrials.gov for “retatrutide” or “LY3437943” and filter by “Recruiting.” Active studies include TRIUMPH-7 (obesity with chronic low back pain), TRIUMPH-8 (general obesity), and TRIUMPH-9 (obesity without type 2 diabetes). You can also call Eli Lilly’s Trial Information Center at 1-877-CTLILLY (1-877-285-4559). Eligibility usually requires a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Participation is free, and legitimate trials cover the study drug, visits, and lab work.
What Are The Most Common Side Effects Of Retatrutide?
The most frequent side effects in trials are gastrointestinal. Nausea, diarrhea, constipation, and vomiting occur most often during dose escalation and usually lessen over time. Dysesthesia, described earlier, is a unique side effect involving altered skin sensations and appears in up to 12.5% of participants at the highest dose. Discontinuation rates due to side effects range from 3.8% to 13.5%, depending on dose and population.
Is Retatrutide Better Than Ozempic?
Trial data suggests retatrutide produces greater average weight loss than semaglutide, the active ingredient in Ozempic and Wegovy. The 28.3% result from TRIUMPH-1 exceeds the roughly 15% reported for semaglutide in STEP-1.1 These comparisons span different trials with different designs, so they are not definitive. Retatrutide also remains under FDA review, while semaglutide has been approved since 2017. For patients who need treatment now, semaglutide and tirzepatide remain well-studied, approved options.
Can I Take Retatrutide If I Have Diabetes?
Retatrutide is being studied in people with type 2 diabetes. TRIUMPH-2 enrolled adults with type 2 diabetes and obesity or overweight, showing up to 20.8% average weight loss and A1C reductions of up to 1.6% at 80 weeks. The TRANSCEND-T2D program is also evaluating retatrutide as a standalone diabetes therapy. Until approval, people with diabetes who are interested in retatrutide can consider clinical trials and should discuss approved alternatives such as tirzepatide or semaglutide with their healthcare provider.
Conclusion: Moving Toward Safe, Evidence-Based Metabolic Care
GLP-3R, or retatrutide, represents a major advance in metabolic medicine, with Phase 3 weight-loss results that approach bariatric surgery and meaningful improvements in cardiovascular risk markers. That promise comes with clear cautions, including ongoing FDA review, common side effects, and a growing market of unsafe, unregulated products that have already triggered regulatory action and rising poison center calls.
Whether you pursue a clinical trial, choose FDA-approved medications, or explore medically supervised peptide therapy, partnering with a qualified provider remains the safest path. At Mirror Plastic Surgery, Dr. Akash Chandawarkar offers concierge-level peptide care that includes comprehensive labs, tailored protocols, vetted products, and 24/7 physician access.
Book Your Consultation At Mirror Plastic Surgery to take a safer, more informed next step toward better metabolic health.
Disclaimer: Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Disclaimer: Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
